Vaxliant

Vaxliant was a biotechnology company specializing in the development of next-generation vaccine adjuvants and delivery systems, primarily for the veterinary market. Established as a joint venture between Agri Laboratories and Benchmark Biolabs, the company provided proprietary platforms like ENABL and Matrix to vaccine developers. These technologies were engineered to enhance the immune response, improve vaccine stability, and minimize adverse reactions at the site of injection. Vaxliant's business model focused on licensing its adjuvant technology to global animal health companies to facilitate the production of more effective vaccines. Following the acquisition of its parent companies by Huvepharma and Merck Animal Health, the joint venture's operations were integrated into the respective acquiring entities.